Abstract

Background Heart failure and left ventricular systolic dysfunction (LVSD) are increasingly common disorders, with outcomes worse than many cancers. Evidence-based therapies, such as ACE inhibitors and beta-blockers, improve prognosis and symptoms, and reduce healthcare expenditure. However, despite the high prevalence and malignant prognosis, few studies have reported the impact of heart failure and LVSD on overall quality of life and, more crucially, have not researched the elderly or those in the community.

Methods All patients attending the Echocardiographic Heart of England Screening (ECHOES) study of the prevalence of heart failure and LVSD in the community were assessed by clinical history and examination, electrocardiogram and echocardiography, and also completed the SF36 health status questionnaire. Quality of life in patients found to have heart failure, LVSD, and other cardiac and medical conditions are compared with the randomly selected general population sample. Data are generalisable to the UK.

Results 6162 people in the community were screened in the ECHOES study, of whom 5961 (97%) completed the SF36. The health perceptions of 3850 people aged 45 years or older selected randomly from the population were compared with those of 426 patients diagnosed as having definite heart failure. Those with heart failure had significant impairment of all the measured aspects of physical and mental health, in addition to declines in physical functioning. Significantly worse impairment was found in those with more severe heart failure by NYHA class: indeed, NYHA functional class was closely correlated to SF36 score. Patients with asymptomatic left ventricular dysfunction and patients rendered asymptomatic by treatment had similar scores to the random population sample. Those with heart failure reported more severe physical impairment of quality of life than people giving a history of chronic lung disease or arthritis, with less impact on mental health than patients reporting depression.

Conclusions Patients with heart failure have statistically significant impairment of all aspects of quality of life, not simply physical functioning. The physical (role and functioning) health burden was significantly greater than that suffered in other serious common chronic disorders, whether cardiac or other systems. Optimising treatment to improve NYHA class appears to improve perceptions of quality of life for patients with heart failure. Given the dramatic decline in quality of life with heart failure, this end-point should be a much more important target for healthcare interventions, especially treatments such as ACE inhibitors and beta-blockers that are shown to improve quality of life. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved

f1
Correspondence: F. D. R. Hobbs, Department of Primary Care and General Practice, Primary Care Clinical Sciences Building, University of Birmingham, Birmingham B15 2TT, U.K.

References

1
Davies
MK
, Hobbs FDR, Davis RC. Prevalence of left ventricular systolic dysfunction and heart failure in the general population: main findings from the ECHOES (Echocardiographic Heart of England Screening) Study.
Lancet
 .
2001
;
358
:
439
–445
2
Bonneaux
L
, Barendregt JJ, Meeter K, Bonsel GJ, van der Maas PJ. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure.
Am J Pub Health
 .
1994
;
84
:
20
–28
3
Hobbs
FDR
, Davis RC, McLeod S. Prevalence of heart failure in ‘high risk’ groups.
J Am Coll Cardiol
 .
1998
;
31
:
85C
4
Ho
KKL
, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after onset of congestive heart failure in Framingham Heart Study subjects.
Circulation
 .
1993
;
88
:
107
–115
5
Calkins
DR
, Rubenstein LV, Cleary PD. Failure of physicians to recognize functional disability in ambulatory patients.
Ann Int Med
 .
1991
;
114
:
451
–454
6
Garg
R
, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.
JAMA
 .
1995
;
273
:
1450
–1456
7
Lechat
P
, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Beta-blockers in heart failure: meta-analysis of randomized trials.
Circulation
 .
1998
;
98
:
1184
–1191
8
Rogers
WJ
, Johnstone DE, Yusuf S. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction.
J Am Coll Cardiol
 .
1994
;
23
:
393
–400
9
N Engl J Med
 .
1991
;
325
:
293
–302
10
N Engl J Med
 .
1992
;
327
:
685
–691
11
Jenkinson
C
, Jenkinson D, Shepperd S, Layte R, Peterson S. Evaluation of treatment for congestive heart failure in patients aged 60 years and older using generic measures of health status (SF-36 and COOP charts).
Age Ageing
 .
1997
;
26
:
7
–13
12
Remes
J
, Miettinen H, Reunanen A, Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care.
Eur Heart J
 .
1991
;
12
:
315
–321
13
Willenheimer
R
, Erhardt L, Cline C, Rydberg E, Israelsson B. Exercise training in heart failure improves quality of life and exercise capacity.
Eur Heart J
 .
1998
;
19
:
774
–781
14
Rich
MW
, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure.
N Engl J Med
 .
1995
;
333
:
1190
–1195
15
Doba
N
, Tomiyama H, Nakayama T. Drugs, heart failure and quality of life: what are we achieving? What should we be trying to achieve?
Drugs Aging
 .
1999
;
14
:
153
–163
16
Krumholz
HM
, Baker DW, Ashton CM. Evaluating quality of care for patients with heart failure.
Circulation
 .
2000
;
101
:
122
–140
17
Rector
TS
, Tschumperlin LK, Kubo SH. Using the living with heart failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death.
J Cardiac Failure
 .
1995
;
1
:
201
–206
18
Konstam
V
, Salem D, Pouleur H. Baseline quality of life as a predictor of mortality and hospitalization in 5025 patients with congestive heart failure.
Am J Cardiol
 .
1996
;
78
:
890
–895
19
Stewart
AL
, Greenfield S, Hays RD. Functional status and well-being of patients with chronic conditions. Results from the medical outcomes study.
JAMA
 .
1989
;
262
:
907
–913
20
Cline
CM
, Willenheimer RB, Erhardt LR, Wiklund I, Israelsonn BY. Health related quality of life in elderly patients with heart failure.
Scand Cardiol J
 .
1999
;
33
:
278
–285
21
Havranek
EP
, Ware MG, Lowes BD. Prevalence of depression in congestive heart failure.
Am J Cardiol
 .
1999
;
84
:
348
–350
22
Murberg
TA
, Bru E, Svebak S, Tveteras R, Aarsland T. Depressed mood and subjective health symptoms as predictors of mortality in patients with congestive heart failure: a two-years follow-up study.
Int J Psych Med
 .
1999
;
29
:
311
–326
23
Eur Heart J
 .
1995
;
16
:
741
–751
24
Ware
JE
Jr
, Sherbourne CD. The MOS 36-item short-form health survey (SF36). I. Conceptual framework and item selection.
Med Care
 .
1992
;
30
:
473
–483
25
Donovan
JL
, Frankel SJ, Eyles JD. Assessing the need for health status measures.
J Epidem Community Health
 .
1993
;
47
:
158
–162
26
Cronbach
LJ
. Coefficient alpha and the internal structure of tests.
Psychometrika
 .
1951
;
16
:
297
–334
27
Hunt
SM
, McEwen J, McKenna SP. Measuring health status. Beckenham: Croom Helm; 1986.
28
Ware
JE
, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston: The Health Institute; 1994.
29
Garratt
AM
, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 health survey questionnaire: an outcome measure suitable for routine use in the NHS?
Br Med J
 .
1993
;
306
:
1440
–1444
30
SAS Institute Inc, SAS/STAT® User's guide, Cary, NC, SAS Institute Inc. 1989
31
Brown
N
, Melville M, Gray D. Quality of life four years after acute myocardial infarction: short form 36 scores compared with a normal population.
Heart
 .
1999
;
81
:
352
–358
32
Rogers
WJ
, Johnstone DE, Yusuf S. Quality of life among 5025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction.
J Am Coll Cardiol
 .
1994
;
23
:
393
–400
33
Jenkinson
C
, Jenkinson D, Shepperd S, Layte R, Peterson S. Evaluation of treatment for congestive heart failure in patients aged 60 years and older using generic measures of health status (SF-36 and COOP charts).
Age Ageing
 .
1997
;
26
:
7
–13
34
Remes
J
, Miettinen H, Reunanen A, Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care.
Eur Heart J
 .
1991
;
12
:
315
–321
35
Cowley
AJ
, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators.
Br Heart J
 .
1994
;
72
:
226
–230
36
Cohen
J
. Statistical power analysis for the behavioural sciences. New Jersey: Lawrence Erlbaum Associates; 1988.

Comments

0 Comments